Placebo and the new physiology of the doctor-patient relationship

Physiological Reviews

Volumn 93, Issue 3, 2013, Pages 1207-1246

  Benedetti, Fabrizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CHOLECYSTOKININ; ENDOCANNABINOID; ENDORPHIN; FLUMAZENIL; FLUOXETINE; MATERIA MEDICA; NALOXONE; NALTREXONE; NARCOTIC AGENT; OXYTOCIN; OXYTOCIN RECEPTOR; RIMONABANT; SEROTONIN TRANSPORTER;

ALTERNATIVE MEDICINE; ANALGESIC ACTIVITY; CLINICAL PRACTICE; CLINICAL RESEARCH; CONDITIONED REFLEX; CONSTIPATION; DOCTOR PATIENT RELATION; DOPAMINE RELEASE; EMPATHY; GENETIC VARIABILITY; HELPLESSNESS; HISTORY OF MEDICINE; HOMEOPATHY; HOPELESSNESS; HUMAN; HYPNOSIS; INTERPERSONAL COMMUNICATION; MAGNETISM; MENTAL DISEASE; NAUSEA; NEUROIMAGING; NEUROPHYSIOLOGY; NONHUMAN; NONVERBAL COMMUNICATION; PAIN THRESHOLD; PATIENT CARE; PERSONALIZED MEDICINE; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESPIRATION DEPRESSION; REVIEW; REWARD; SIGNAL DETECTION; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL STATUS; STATE DEPENDENT LEARNING; TRANSCRANIAL MAGNETIC STIMULATION; URINE RETENTION; VISUAL STIMULATION;

BRAIN; HUMANS; PHYSICIAN-PATIENT RELATIONS; PLACEBO EFFECT; PLACEBOS;

EID: 84880933259     PISSN: 00319333     EISSN: 15221210     Source Type: Journal    
DOI: 10.1152/physrev.00043.2012     Document Type: Review

References (356)

1. Abramson LY, Metalsky GI, Alloy LB. Hopelessness depression: a theory-based subtype of depression. Psychol Rev 96: 358-372, 1989.
2. Abramson LY, Seligman MEP, Teasdale J. Learned helplessness in humans: critique and reformulation. J Abn Psychol 87: 49-74, 1978.
3. Ader R. The role of conditioning in pharmacotherapy. In: The Placebo Effect: An Interdisciplinary Exploration, edited by Harrington A. Cambridge, MA: Harvard Univ. Press, 1997, p. 138-165.
4. Ader R, Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med 37: 333-340, 1975.
5. Ader R, Cohen N. Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus. Science 215: 1534-1536, 1982.
6. Ader R, Kelly K, Moynihan JA, Grota LJ, Cohen N. Conditioned enhancement of antibody production using antigen as the unconditioned stimulus. Brain Behav Immunity 7: 334-343, 1993.
7. Ader R, Mercurio MG, Walton J, James D, Davis Ojha VM, Kimball AB, Fiorentino D. Conditioned pharmacotherapeutic effects: a preliminary study. Psychosom Med 72: 192-197, 2010.
8. Adolphs R, Tranel D, Damasio AR. The human amygdala in social judgment. Nature 393: 470-474, 1998.
9. Adolphs R, Tranel D, Damasio H, Damasio A. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature 372: 669-672, 1994.
10. Affleck G, Tennen H. Construing benefits from adversity: adaptational significance and dispositional underpinnings. J Personality 64: 899-922, 1996.
11. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381, 1986.
12. Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. Eval Health Prof 25: 410-420, 2002.
13. Alvarez-Borda B, Ramirez-Amaya V, Pèrez-Montfort R, Bermùdez-Rattoni F. Enhancement of antibody production by a learning paradigm. Neurobiol Learning Memory 64: 103-105, 1995.
14. Alvarez-Buyalla R, Carrasco-Zanini J. A conditioned reflex which reproduces the hypoglycemic effect of insulin. Acta Physiol Latino Americana 10: 153-158, 1960.
15. Alvarez-Buyalla R, Segura ET, Alvarez-Buyalla ER. Participation of the hypophysis in the conditioned reflex which reproduces the hypoglycemic effect of insulin. Acta Physiol Latino Americana 11: 113-119, 1961.
16. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 19: 484-494, 1999.
17. Amanzio M, Benedetti F, Porro CA, Palermo S, Cauda F. Activation likelihood estimation meta-analysis of brain correlates of placebo analgesia in human experimental pain. Hum Brain Mapp doi:10.1002/hbm.21471.
18. Amanzio M, Latini Corazzini L, Vase L, Benedetti F. An analysis of adverse events in placebo groups of anti-migraine clinical trials. Pain 146: 261-269, 2009.
19. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90: 205-215, 2001.
20. Amat J, Matus-Amat P, Watkins LR, Maier SF. Escapable and inescapable stress differentially and selectively alter extracellular levels of 5-HT in the ventral hippocampus and dorsal periaqueductal gray of the brain. Brain Res 797: 12-22, 1998.
21. Andre J, Zeau B, Pohl M, Cesselin F, Benoliel JJ, Becker C. Involvement of cholecystokininergic systems in anxyety-induced hyperalgesia in male rats: behavioral and biochemical studies. J Neurosci 25: 7896-7904, 2005.
22. André-Obadia N, Magnin M, Garcia-Larrea L. On the importance of placebo timing in rTMS studies for pain relief. Pain 152: 1233-1237, 2011.
23. Andrews G. Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry 178: 192-194, 2001.
24. Ariel G, Saville W. Anabolic steroids: the physiological effects of placebos. Med Sci Sports Exerc 4: 124-126, 1972.
25. Atlas LY, Whittington RA, Lindquist MA, Wielgosz J, Sonty N, Wager TD. Dissociable effects of opiates and expectations on pain. J Neurosci 32: 8053-8064, 2012.
26. Bakermans-Kranenburg MJ, van Ijzendoorn MH. Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting. Soc Cogn Affect Neurosci 3: 128-134, 2008.
27. Balint M. The doctor, his patient, and the illness. Lancet 1: 683-688, 1955.
28. Barnum DD, Snyder CR, Rapoff MA, Mani MM, Thompson R. Hope and social support in the psychological adjustment of pediatric burn survivors and matched controls. Children's Health Care 27: 15-30, 1998.
29. Baron-Cohen S. Mindblindness: An Essay on Autism and Theory of Mind. Cambridge, MA: MIT Press, 1995.
30. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287: 622-627, 2002.
31. Bartz JA, Hollander E. The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Hormones Behav 50: 518-528, 2006.
32. Batson CD, Eklund JH, Chermok VL, Hoyt JL, Ortiz BG. An additional antecedent of empathic concern: valuing the welfare of the person in need. J Personality Soc Psychol 93: 65-74, 2007.
33. Batterman RC. Persistence of responsiveness with placebo therapy following an effective drug trial. J New Drugs 6: 137-141, 1966.
34. Batterman RC, Lower WR. Placebo responsiveness: influence of previous therapy. Curr Ther Res 10: 136-143, 1968.
35. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58: 639-650, 2008.
36. Beecher HK. The powerful placebo. JAMA 159: 1602-1606, 1955.
37. Beedie CJ, Coleman DA, Foad AJ. Positive and negative placebo effects resulting from the deceptive administration of an ergogenic aid. Int J Sport Nutr Exerc Metab 17: 259-269, 2007.
38. Beedie CJ, Foad AJ, Coleman DA. Identification of placebo responsive participants in 40km laboratory cycling performance. J Sports Sci Med 7: 166-175, 2008.
39. Beedie CJ, Stuart EM, Coleman DA, Foad AJ. Placebo effect of caffeine in cycling performance. Med Sci Sports Exerc 38: 2159-2164, 2006.
40. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64: 535-543, 1996.
41. Benedetti F. How the doctor's words affect the patient's brain. Eval Health Prof 25: 369-386, 2002.
42. Benedetti F. Placebo and endogenous mechanisms of analgesia. Handb Exp Pharmacol 177: 393-413, 2007.
43. Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48: 33-60, 2008.
44. Benedetti F. Placebo effects: understanding the mechanisms in health and disease. Oxford, uk: Oxford Univ. Press, 2008.
45. Benedetti F. No prefrontal control, no placebo response. Pain 148: 357-358, 2010.
46. Benedetti F. The Patient's Brain: The Neuroscience Behind the Doctor-Patient Relationship. Oxford, UK: Oxford Univ. Press, 2010.
47. Benedetti F. The placebo response: science versus ethics and the vulnerability of the patient. World Psychiatry 11: 70-72, 2012.
48. Benedetti F, Amanzio M, Baldi S, Casadio C, Cavallo A, Mancuso M, Ruffini E, Oliaro A, Maggi G. The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain 75: 313-319, 1998.
49. Benedetti F, Amanzio M, Baldi S, Casadio C, Maggi G. Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci 11: 625-631, 1999.
50. Benedetti F, Amanzio M, Casadio C, Oliaro A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 71: 135-140, 1997.
51. Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 346: 1231, 1995.
52. Benedetti F, Amanzio M, Rosato R, Blanchard C. Non-opioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Med 17: 1228-1230, 2011.
53. Benedetti F, Amanzio M, Thoen W. Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology 213: 791-797, 2011.
54. Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 26: 12014-12022, 2006.
55. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-expectations of analgesia. J Neurosci 9: 3639-3648, 1999.
56. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I, Asteggiano G. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 121: 133-144, 2006.
57. Benedetti F, Carlino E, Pollo A. Hidden administration of drugs. Clin Pharmacol Ther 90: 651-661, 2011.
58. Benedetti F, Colloca L, Lanotte M, Bergamasco B, Torre E, Lopiano L. Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res Bull 63: 203-211, 2004.
59. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, Bergamasco B, Lopiano L. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci 7: 587-588, 2004.
60. Benedetti F, Lanotte M, Colloca L, Ducati A, Zibetti M, Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol 587: 3869-3883, 2009.
61. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147: 260-271, 2007.
62. Benedetti F, Maggi G, Lopiano Lanotte ML, Rainero I, Vighetti S, Pollo A. Open versus hidden medical treatments: the patient's knowledge about a therapy affects the therapy outcome. Prevention Treatment 2003. Available online at: http://journals.apa.org/prevention/volume6/toc-jun-03.html.
63. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci 25: 10390-10402, 2005.
64. Benedetti F, Pollo A, Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? J Neurosci 27: 11934-11939, 2007.
65. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor and hormonal placebo/nocebo responses. J Neurosci 23: 4315-4323, 2003.
66. Benedetti F, Thoen W, Blanchard C, Vighetti S, Arduino C. Pain as a reward: changing the meaning of pain from negative to positive co-activates opioid and cannabinoid systems. Pain. In press.
67. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. Patient Educ Couns 80: 293-299, 2010.
68. Bentin S, Degutis JM, D'Esposito M, Robertson LC. Too many trees to see the forest: Performance, event-related potential, and functional magnetic resonance imaging manifestations of integrative congenital prosopagnosia. J Cogn Neurosci 19: 132-146, 2007.
69. Bergman H, Wichmann T, Karmon B, DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507-520, 1994.
70. Bingel U, Lorenz J, Schoell E, Weiller C, Büchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 120: 8-15, 2005.
71. Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee LC, Ploner M, Tracey I. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Trans Med 3: 70ra14, 2011.
72. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62: 63-88, 2000.
73. Booth RJ, Petrie KJ, Brook RJ. Conditioning allergic skin responses in humans: a controlled study. Psychosom Med 57: 492-495, 1995.
74. Bovbjerg D, Ader R, Cohen N. Acquisition and extinction of conditioned suppression of a graft-versus-host response in the rat. J Immunol 132: 111-113, 1984.
75. Breznitz S. The effect of hope on pain tolerance. Social Res 66: 629-652, 1999.
76. Brody H. The Placebo Response. New York: Harper Collins, 2000.
77. Brody H, Colloca L, Miller FG. The placebo phenomenon: implications for the ethics of shared decision-making. J Gen Intern Med 27: 739-742, 2012.
78. Broks P, Young AW, Maratos EJ, Coffey PJ, Calder AJ, Isaac CL, Mayes AR, Hodges JR, Montaldi D, Cezayirli E, Roberts N, Hadley D. Face processing impairments after encephalitis: amygdala damage and recognition of fear. Neuropsychologia 39: 59-70, 1998.
79. Cannon WB. Voodoo death. Am Anthropologist 44: 169-181, 1942.
80. Casey TP. Immunosuppression by cyclophosphamide in NZB/NZW mice with lupus nephritis. Blood 32: 436-444, 1968.
81. Chartrand TL, Bargh JA. The chameleon effect: the perception behavior link and social interaction. J Personality Social Psychol 76: 893-910, 1999.
82. Chen J, Lin W, Wang W, Shao F, Yang J, Wang B, Kuang F, Duan X, Ju G. Enhancement of antibody production and expression of c-Fos in the insular cortex in response to a conditioned stimulus after a single-trial learning paradigm. Behav Brain Res 154: 557-565, 2004.
83. Cheng Y, Lin CP, Liu HL, Hsu YY, Lim KE, Hung D, Decety J. Expertise modulates the perception of pain in others. Curr Biol 17: 1708-1713, 2007.
84. Chua P, Krams M, Toni I, Passingham R, Dolan R. A functional anatomy of anticipatory anxiety. Neuroimage 9: 563-571, 1999.
85. Clark VR, Hopkins WG, Hawley JA, Burke LM. Placebo effect of carbohydrate feedings during a 40-km cycling time trial. Med Sci Sports Exerc 32: 1642-1647, 2000.
86. Clark WC. Sensory-decision theory analysis of the placebo effect on the criterion for pain and thermal sensitivity. J Abn Psychol 74: 363-371, 1969.
87. Coan JA, Schaefer HS, Davidson RJ. Lending a hand. Social regulation of the neural response to threat. Psychol Sci 17: 1032-1039, 2006.
88. Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6: 545-552, 2005.
89. Colloca L, Benedetti F. How prior experience shapes placebo analgesia. Pain 124: 126-133, 2006.
90. Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol 20: 435-439, 2007.
91. Colloca L, Benedetti F. Placebo analgesia induced by social observational learning. Pain 144: 28-34, 2009.
92. Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety and Parkinson's disease. Lancet Neurol 3: 679-684, 2004.
93. Colloca L, Tinazzi M, Recchia S, Le Pera D, Fiaschi A, Benedetti F, Valeriani M. Learning potentiates neurophysiological and behavioral placebo analgesic responses. Pain 139: 306-314, 2008.
94. Cormie PJ, Nairn M, Welsh J, Guideline Development Group. Control of pain in adults with cancer: summary of SIGN guidelines. Br Med J 337: a2154, 2008.
95. Damasio AR, Tranel D, Damasio H. Face agnosiaand the neural substrates of memory. Annu Rev Neurosci 13: 89-109, 1990.
96. Dannecker EA, Price DD, Robinson ME. An examination of the relationships among recalled, expected, and actual intensity and unpleasantness of delayed onset muscle pain. J Pain 4: 74-81, 2003.
97. Davis CE. Regression to the mean or placebo effect? In: The Science of the Placebo: Toward an Interdisciplinary Research Agenda, edited by Guess HA, Kleinman A, Kusek JW, and Engel LW, London: British Medical Journal Books, 2002, p. 15874-166.
98. Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136: 359-363, 2002.
99. Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164-1166, 2001.
100. De Pascalis V, Chiaradia C, Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 96: 393-402, 2002.
101. De Waal FB. Putting the altruism back into altruism: the evolution of empathy. Annu Rev Psychol 59: 279-300, 2008.
102. Decety J, Jackson PL. The functional architecture of human empathy. Behav Cogn Neurosci Rev 3: 71-100, 2004.
103. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effect on health outcomes: a systematic review. Lancet 357: 757-762, 2001.
104. Dias R, Robbins TW, Roberts AC. Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380: 69-72, 1996.
105. Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 65: 728-731, 2009.
106. Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmaco-therapy. Trends Pharmacol Sci 33: 165-172, 2012.
107. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves "mindreading" in humans. Biol Psychiatry 61: 731-733, 2007.
108. Duchaine BC, Parker H, Nakayama K. Normal emotion recognition in a developmental prosopagnosic. Perception 32: 827-838, 2003.
109. Dunbar RIM. The social role of touch in humans and primates: behavioural function and neurobiological mechanisms. Neurosci Biobehav Rev 34: 260-268, 2010.
110. Dworkin SF, Chen AC, LeResche L, Clark DW. Cognitive reversal of expected nitrous oxide analgesia for acute pain. Anesth Analg 62: 1073-1077, 1983.
111. Eccles R. The powerful placebo in cough studies. Pulm Pharmacol Ther 15: 303-308, 2002.
112. Eccles R. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol Neurobiol 152: 340-348, 2006.
113. Edwards E, Harkins K, Wright G, Henn FA. 5-HT1b receptors in an animal model of depression. Neuropharmacology 30: 101-105, 1991.
114. Edwards E, Kornich W, Houtten PV, Henn FA. Presynaptic serotonin mechanisms in rats subjected to inescapable shock. Neuropharmacology 31: 323-330, 1992.
115. Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, Büchel C. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63: 533-543, 2009.
116. Eippert F, Finsterbusch J, Bingel U, Büchel C. Direct evidence for spinal cord involvement in placebo analgesia. Science 326: 404, 2009.
117. Eisenberg N. Empathy-related responding and prosocial behaviour. Novartis Found Symposia 278: 71-80, 2007.
118. Emery NJ. The eyes have it: the neuroethology, function and evolution of social gaze. Neurosci Biobehav Rev 24: 581-604, 2000.
119. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron 59: 195-206, 2008.
120. Engel GL. A life setting conducive to illness: the givingup-given-up complex. Ann Int Med 69: 293-299, 1968.
121. Engell AD, Haxby JV, Todorov A. Implicit trustworthiness decisions: automatic coding of face properties in human amygdala. J Cogn Neurosci 19: 1508-1519, 2007.
122. Evans FJ. The placebo control of pain: a paradigm for investigating non-specific effects in psychotherapy. In: Psychiatry: Areas of Promise and Advancement, edited by Brady JP, Mendels J, Reiger WR, and Orne MT, New York: Plenum, 1977, p. 249-271.
123. Exton MS, von Horsten SB, Schult M, Voege J, Strubel T, Donath S, Steinmueller C, Seeliger H, Nagel E, Westermann J, Schedlowski M. Behaviourally conditioned immunosuppression using cyclosporine A: central nervous system reduces IL-2 production via splenic innervation. J Neuroimmunol 88: 182-191, 1998.
124. Fehm-Wolfsdorf G, Beermann U, Kern W, Fehm HL. Failure to obtain classical conditioned hypoglycemia in man. In: Neuronal Control of Bodily Function: Basic and Clinical Aspects. Endocrine and Nutritional Control of Basic Biological Functions, edited by Lehnert H, Murison R, Weiner H, Hellhammer D, and Beyer J Jr. Seattle: Hogrefe & Huber, 1993, p. 257-261.
125. Fehm-Wolfsdorf G, Gnadler M, Kern W, Klosterhalfen W, Kerner W. Classically conditioned changes of blood glucose level in humans. Physiol Behav 54: 155-160, 1993.
126. Fehm-Wolfsdorf G, Pohl J, Kerner W. Classically conditioned changes of blood glucose level in humans. Integr Physiol Behav Sci 34: 132, 1999.
127. Ferrell BR, Dean G. The meaning of cancer pain. Semin Oncol Nurs 11: 17-22, 1995.
128. Fields HL, Levine JD. Placebo analgesia: a role for endorphins? Trends Neurosci 7: 271-273, 1984.
129. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686-695, 2010.
130. Flaten MA, Simonsen T, Olsen H. Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 61: 250-255, 1999.
131. Flor H, Grusser SM. Conditioned stress-induced analgesia in humans. Eur J Pain 3: 317-324, 1999.
132. Foad AJ, Beedie CJ, Coleman DA. Pharmacological and psychological effects of caffeine ingestion in 40-km cycling performance. Med Sci Sport Exerc 40: 158-165, 2008.
133. Report of Dr. Benjamin Franklin, and Other Commissioners, Charged by the King of France, With the Examination of Animal Magnetism, as Now Practiced in Paris, translated by Godwin W. London: Johnson, 1785.
134. Frith CD, Frith U. Interacting minds: a biological basis. Science 286: 1692-1695, 1999.
135. Frith CD, Frith U. The neural asis of mentalizing. Neuron 50: 531-534, 2006.
136. Frith U, Frith CD. Development and neurophysiology of mentalizing. Phil Trans R Soc Lond B Biol Sci 358: 459-473, 2003.
137. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, Pissiota A, Frans O, Bani M, Bettica P, Pich EM, Jacobsson E, Wahlstedt K, Oreland L, Langstrom B, Eriksson E, Fredrikson M. A link between serotonin-related gene polymorphisms, amygdala activity, and lacebo-induced relief from social anxiety. J Neurosci 28: 13066-13074, 2008.
138. Gauci M, Husband AJ, Saxarra H, King MG. Pavlovian conditioning of nasal tryptase release in human subjects with allergic rhinitis. Physiol Behav 55: 823-825, 1994.
139. Geers AL, Helfer SG, Kosbab K, Weiland PE, Landry SJ. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res 58: 121-127, 2005.
140. Geers AL, Kosbab K, Helfer SG, Weiland PE, Wellman JA. Further evidence for individual differences in placebo responding: an interactionist perspective. J Psychosom Res 62: 563-570, 2007.
141. Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N, Ader R. Conditioning of cyclophosphamide-induced leukopenia in humans. J Neuropsychiatry Clin Neurosci 8: 194-201, 1996.
142. Goebel MU, Huebell D, Kou W, Janssen OE, Katsarava Z, Limmroth V, Schedlowski M. Behavioural conditioning with interferon beta-1a in humans. Physiol Behav 84: 807-814, 2005.
143. Goebel MU, Meykadeh N, Kou W, Schedlowski M, Hengge UR. Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom 77: 227-234, 2009.
144. Goebel MU, Trebst AE, Steiner J, Xie YF, Exton MS, Frede S, Canbay AE, Michel MC, Heemann U, Schedlowski M. Behavioral conditioning of immunosuppression is possible in humans. FASEB J 16: 1869-1873, 2002.
145. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology 54: 710-714, 2000.
146. Gorczynski RM, Macrae S, Kennedy M. Conditioned immune response associated with allogeneic skin grafts in mice. J Immunol 129: 704-709, 1982.
147. Gracely RH, Dubner R, Wolskee PJ, Deeter WR. Placebo and naloxone can alter postsurgical pain by separate mechanisms. Nature 306: 264-265, 1983.
148. Grevert P, Albert LH, Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain 16: 129-143, 1983.
149. Grochowicz P, Schedlowski M, Husband AJ, King MG, Hibberd AD, Bowen KM. Behavioral conditioning prolongs heart allograft survival in rats. Brain Behav Immunity 5: 349-356, 1991.
150. Guo JY, Wang JY, Luo F. Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. J Psychopharmacol 24: 1561-1567, 2010.
151. Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 26: 317-330, 2003.
152. Hahn RA. A sociocultural model of illness and healing. In: Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, and Schwartz GE. New York: Guilford, 1985, p. 332.
153. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 26: 607-611, 1997.
154. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 7: e48135, 2012.
155. Hampson DB, St Clair Gibson A, Lambert MI, Noakes TD. The influence of sensory cues on the perception of exertion during exercise and central regulation of exercise performance. Sports Med 31: 935-952, 2001.
156. Harrington A. The Placebo Effect: An Interdisciplinary Exploration. Cambridge, MA: Harvard Univ. Press, 1997.
157. Harris GC, Fitzgerald RD. Impaired learning of classically conditioned bradycardia inrats following fourth ventricle administration of D-Ala2-methionine-enkephalinamide. Behav Neurosci 103: 77-83, 1989.
158. Hashmi JA, Baria AT, Baliki MN, Huang L, Schnitzer TJ, Apkarian AV. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain 153: 2393-2402, 2012.
159. Häuser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int 109: 459-465, 2012.
160. Haygarth J. Of the Imagination, as a Cause and as a Cure of Disorders of the Body; Exemplified by Fictitious Tractors and Epidemical Convulsions. Bath, UK: Cruttwell, 1801.
161. Hein G, Singer T. I feel how you feel but not always: the empathic brain and its modulation. Curr Opin Neurobiol 18: 153-158, 2008.
162. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54: 1389-1398, 2003.
163. Heinrichs M, Domes G. Neuropeptides and social behavior: effects of oxytocin and vasopressin in humans. Prog Brain Res 170: 337-350, 2008.
164. Henderson SW. The unnatural nature of pain. JAMA 283: 117, 2000.
165. Henkel V, Bussfeld P, Moller HJ, Hegerl U. Cognitive-behavioural theories of helplessness/hopelessness: valid models for depression? Eur Arch Psychiatry Clin Neurosci 252: 240-249, 2002.
166. Hernandez LL, Powell DA. Naloxone induces multiple effects on aversive Pavlovian conditioning in rabbits. Behav Neurosci 97: 478-491, 1983.
167. Hernandez LL, Powell DA, Gibbs CM. Amygdaloid central nucleus neuronal activity accompanying pavlovian cardiac conditioning: effects of naloxone. Behav Brain Res 41: 71-79, 1990.
168. Hernandez LL, Watson KL. Opioid modulation of attention-related responses: deltareceptors modulate habituation and conditioned bradycardia. Psychopharmacology 131: 140-147, 1997.
169. Herrnstein RJ. Placebo effect in the rat. Science 138: 677-678, 1962.
170. Hsieh JC, Stone-Elander S, Ingvar M. Anticipatory coping of pain expressed in the human anterior cingulated cortex: a positron emission tomography study. Neurosci Lett 262: 61-64, 1999.
171. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248, 2005.
172. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Rev 31: 6-41, 1999.
173. Immordino-Yang MH, McColl A, Damasio H, Damasio A. Neural correlates of admiration and compassion. Proc Nat Acad Sci USA 106: 8021-8026, 2009.
174. Jabbi M, Swart M, Keysers C. Empathy for positive and negative emotions in the gustatory cortex. Neuroimage 34: 1744-1753, 2007.
175. Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, Gollub RL, Ingvar M, Kong J. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci USA 109: 15959-15964, 2012.
176. Kalivas PW, Churchill L, Romanides A. Involvement of the pallidal-thalamocortical circuit in adaptive behaviour. Ann NY Acad Sci 877: 64-70, 1999.
177. Kanwisher NG, McDermott J, Chun MM. The fusiform face area: A module in human extrastriate cortex specialized for face perception. J Neurosci 17: 4302-4311, 1997.
178. Kaptchuk TJ. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull History Med 72: 389-433, 1998.
179. Kawashima R, Sugiura M, Kato T, Nakamura A, Hatano K, Ito K, Fukuda H, Kojima S, Nakamura K. The human amygdala plays an important role in gaze monitoring. A PET study. Brain 122: 779-783, 1999.
180. Keltner JR, Furst A, Fan C, Redfern R, Inglis B, Fields HL. Isolating the modulatory effect of expectation on pain transmission: a functional magnetic imaging study. J Neurosci 26: 4437-4443, 2006.
181. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, Kline JN. Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol 119: 1375-1381, 2007.
182. Keysers C, Wicker B, Gazzola V, Anton JL, Forgassi L, Gallese V. A touching sight: SII/PV activation during the observation and experience of touch. Neuron 42: 335-346, 2004.
183. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. Arch Gen Psychiatry 57: 311-317, 2000.
184. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction? J Clin Epidemiol 50: 1311-1318, 1997.
185. Kim JW, Kim SE, Kim JJ, Jeong B, Park CH, Son AR, Song JE, Ki SW. Compassionate attitude towards others' suffering activates the mesolimbic neural system. Neuropsychologia 47: 2073-2081, 2009.
186. Kirk JM, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 59: 287-293, 1998.
187. Kirsch I. Response expectancy as determinant of experience and behavior. Am Psychologist 40: 1189-1202, 1985.
188. Kirsch I. How Expectancies Shape Experience. Washington, DC: Am. Psychol. Assoc., 1999.
189. Kirsch I, Lynn SJ, Vigorito M, Miller RR. The role of cognition in classical and operant conditioning. J Clin Psychol 60: 369-392, 2004.
190. Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention Treatment 1998, Available online at http://journals.apa.org/prevention/volume1/pre0010002a.html.
191. Kirschbaum C, Jabaij L, Buske-Kirschbaum A, Hennig J, Blom M, Dorst K, Bauch J, Di Pauli R, Schmitz G, Ballieux R. Conditioning of drug-induced immunomodulation in human volunteers: a European collaborative study. Br J Clin Psychol 31: 459-472, 1992.
192. Klosterhalfen W, Klosterhalfen S. Pavlovian conditioning of immunosuppression modifies adjuvant arthritis in rats. Behav Neurosci 97: 663-666, 1983.
193. Knutson B, Cooper JC. Functional magnetic resonance imaging of reward prediction. Curr Opin Neurol 18: 411-417, 2005.
194. Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ. Cultural meanings of pain: a qualitative study of Black Carribean and White British patients with advanced cancer. Palliat Med 22: 350-359, 2008.
195. Kong J, Gollub RL, Polich G, Kirsch I, Laviolette P, Vangel M, Rosen B, Kaptchuk TJ. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci 28: 13354-13362, 2008.
196. Kong J, Gollub RL, Rosman I, Webb JM, Vangel MG, Kirsch I, Kaptchuk TJ. Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J Neurosci 26: 381-388, 2006.
197. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 435: 673-676, 2005.
198. Koyama T, McHaffie JG, Laurienti PJ, Coghill RC. The subjective experience of pain: where expectations become reality. Proc Natl Acad Sci USA 102: 12950-12955, 2005.
199. Koyama T, Tanaka YZ, Mikami A. Nociceptive neurons in the macaque anterior cingulate activate during anticipation of pain. Neuroreport 9: 2663-2667, 1998.
200. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry 65: 1174-1179, 2004.
201. Krummenacher P, Candia V, Folkers G, Schedlowski M, Schönbächler G. Prefrontal cortex modulates placebo analgesia. Pain 148: 368-374, 2010.
202. Lambert EV, St Clair Gibson A, Noakes TD. Complex systems model of fatigue: integrative homoeostatic control of peripheral physiological systems during exercise in humans. Br J Sports Med 39: 52-62, 2005.
203. Lanotte M, Lopiano L, Torre E, Bergamasco B, Colloca L, Benedetti F. Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region. Brain Behav Immunity 19: 500-509, 2005.
204. Laska E, Sunshine A. Anticipation of analgesia a placebo effect. Headache 13: 1-11, 1973.
205. Lazarus RS. Hope: an emotion and a vital coping resource against despair. Social Res 66: 665-669, 1999.
206. Lee PCL, Jawad MSM, Hull JD, West WHL, Shaw K, Eccles R. The antitussive effect of placebo treatment on cough associated with acute upper respiratory infection. Psychosom Med 67: 314-317, 2005.
207. Leech J, Mazzone SB, Farrell MJ. The effect of placebo conditioning on capsaicinevoked urge-to-cough. Chest. In press.
208. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159: 122-129, 2002.
209. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 29: 372-377, 2009.
210. Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature 312: 755-756, 1984.
211. Levine JD, Gordon NC, Bornstein JC, Fields HL. Role of pain in placebo analgesia. Proc Nat Acad Sci USA 76: 3528-3531, 1979.
212. Levine JD, Gordon NC, Fields HL. The mechanisms of placebo analgesia. Lancet 2: 654-657, 1978.
213. Levine JD, Gordon NC, Smith R, Fields HL. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain 10: 379-389, 1981.
214. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86: 249-260, 2001.
215. Lewis G. Fear of sorcery and the problem of death by suggestion. In: The Anthropology of the Body, edited by Blacking J. New York: Academic, 1977.
216. Lichko AE. Conditioned reflex hypoglycaemia in man. Pavlovian J High Nerv Activity 9: 731-737, 1959.
217. Lidstone SC, Schulzer M, Dinelle K, Mak E, Sossi V, Ruth TJ, de la Fuente-Fernandez R, Phillips AG, Stoessl AJ. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67: 857-865, 2010.
218. Lieberman MD, Jarcho JM, Berman S, Naliboff BD, Suyenobu BY, Mandelkern M, Mayer EA. The neural correlates of placebo effects: a disruption account. Neuroimage 22: 447-455, 2004.
219. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339: 1105-1111, 1998.
220. Lipman JJ, Miller BE, Mays KS, Miller MN, North WC, Byrne WL. Peak B endorphin concentration in cerebrospinal fluid: reduced in chronic pain patients and increased during the placebo response. Psychopharmacology 102: 112-116, 1990.
221. Longo DL, Duffey PL, Kopp WC, Heyes MP, Alvord WG, Sharfman WH, Schmidt PJ, Rubinow DR, Rosenstein DL. Conditioned immune response to interferon-γ in humans. Clin Immunol 90: 173-181, 1999.
222. Lordkipanidze D, Vekua A, Ferring R, Rightmire GP, Agusti J, Kiladze G, Mouskhelshvili A, Nioradze M, Ponce de Leon MS, Tappen M, Zollikofer CP. Anthropology: the earliest toothless hominin skull. Nature 434: 717-718, 2005.
223. Lorenz J, Hauck M, Paur RC, Nakamura Y, Zimmermann R, Bromm B, Engel AK. Cortical correlates of false expectations during pain intensity judgments-a possible manifestation of placebo/nocebo cognitions. Brain Behav Immunity 19: 283-295, 2005.
224. Lui F, Colloca L, Duzzi D, Anchisi D, Benedetti F, Porro CA. Neural bases of conditioned placebo analgesia. Pain 151: 816-824, 2010.
225. Luparello TJ, Lyons HA, Bleeker ER, McFadden ER. Influence of suggestion on airways reactivity in asthmatic subjects. Psychosom Med 30: 819-825, 1968.
226. Lysle DT, Luecken LJ, Maslonek KA. Suppression of the development of adjuvant arthritis by a conditioned aversive stimulus. Brain Behav Immunity 6: 64-73, 1992.
227. Maganaris CN, Collins D, Sharp M. Expectancy effects and strength training: do steroids make a difference? Sport Psychologist 14: 272-278, 2000.
228. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 4: 819-828, 2003.
229. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA. The functional neuroanatomy of the placebo effect. Am J Psychiatry 159: 728-737, 2002.
230. McClung M, Collins D. "Because I know it will!": placebo effects of an ergogenic aid on athletic performance. J Sport Exerc Psychol 29: 382-394, 2007.
231. McGlashan TH, Evans FJ, Orne MT. The nature of hypnotic analgesia and placebo response to experimental pain. Psychosom Med 31: 227-246, 1969.
232. McNaughton LR. Sodium bicarbonate ingestion and its effects on anaerobic exercise of various durations. J Sport Sci 10: 425-435, 1992.
233. McRae C, Cherin E, Yamazaki G, Diem G, Vo AH, Russell D, Ellgring JH, Fahn S, Greene P, Dillon S, Winfield H, Bjugstad KB, Freed CR. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 61: 412-420, 2004.
234. Meissner K, Bingel U, Colloca L, Wager TD, Watson A, Flaten MA. The placebo effect: advances from different methodological approaches. J Neurosci 31: 16117-16124, 2011.
235. Mercado R, Constantoyannis C, Mandat T, Kumar A, Schulzer M, Stoessl AJ, Honey CR. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord 21: 1457-1461, 2006.
236. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167-202, 2001.
237. Miller FG, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioeth 9: 39-47, 2009.
238. Miller FG, Colloca L. The placebo phenomenon and medical ethics: rethinking the relationship between informed consent and risk-benefit assessment. Theor Med Bioeth 32: 229-243, 2011.
239. Moerman DE. Meaning, Medicine and the Placebo Effect. Cambridge, UK: Cambridge Univ. Press, 2002.
240. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Int Med 136: 471-476, 2002.
241. Mogenson GJ, Yang CA. The contribution of basal forebrain to limbic-motor integration and the mediation of motivation to action. Adv Exp Med Biol 295: 267-290, 1991.
242. Montgomery GH, Kirsch I. Mechanisms of placebo pain reduction: an empirical investigation. Psychol Sci 7: 174-176, 1996.
243. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain 72: 107-113, 1997.
244. Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 366: 1879-1888, 2011.
245. Morris AD, Esterly J, Chase G, Sharp GC. Cyclophosphamide protection in NZB/ NZW disease. Arthritis Rheumatism 19: 49-55, 1976.
246. Noakes TD. Fatigue is a brain-derived emotion that regulates the exercise behavior to ensure the protection of whole body homeostasis. Front Physiol 3: 82, 2012.
247. Nolan TA, Price DD, Caudle RM, Murphy NP, Neubert JK. Placebo-induced analgesia in an operant pain model in rats. Pain 153: 2009-2016, 2012.
248. Oftedal G, Straume A, Johnsson A, Stovner LJ. Mobile phone headache: a double blind, sham-controlled provocation study. Cephalalgia 27: 447-455, 2007.
249. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54: 403-414, 2003.
250. Olness K, Ader R. Conditioning as an adjunct in the pharmacotherapy of lupus erythematosus. J Dev Behav Pediatr 13: 124-125, 1992.
251. Overmier JB, Seligman MEP. Effects of inescapable shock upon subsequent escape and avoidance learning. J Comp Physiol Psychol 63: 23-33, 1967.
252. Pacheco-Lopez G, Engler H, Niemi MB, Schedlowski M. Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology. Brain Behav Immunity 20: 430-446, 2006.
253. Pacheco-Lopez G, Niemi MB, Kou W, Harting M, Fandrey J, Schedlowski M. Neural substrates for behaviorally conditioned immunosuppression in the rat. J Neurosci 25: 2330-2337, 2005.
254. Pearson SD, Raeke LH. Patients' trust in physicians: many theories, few measures, and little data. J Gen Int Med 15: 509-513, 2000.
255. Peterson C, Seligman MEP, Vaillant G. Pessimistic explanatory style is a risk factor for physical illness: a thirty-five year longitudinal follow-up. J Personality Social Psychol 55: 23-27, 1988.
256. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K. Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46: 957-969, 2005.
257. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia-imaging a shared neuronal network. Science 295: 1737-1740, 2002.
258. Ploghaus A, Tracey I, Gati JS, Clare S, Menon RS, Matthews PM, Rawlins JN. Dissociating pain from its anticipation in the human brain. Science 284: 1979-1981, 1999.
259. Pogge RC. The toxic placebo. Part I. Side and toxic effects reported during the administration of placebo medicine. Med Times 91: 773-778, 1963.
260. Pollo A, Carlino E, Benedetti F. The top-down influence of ergogenic placebos on muscle work and fatigue. Eur J Neurosci 28: 379-388, 2008.
261. Pollo A, Carlino E, Vase L, Benedetti F. Preventing motor training through nocebo suggestions. Eur J Appl Physiol 112: 3893-3903, 2012.
262. Pollo A, Torre E, Lopiano L, Rizzone M, Lanotte M, Cavanna A, Bergamasco B, Benedetti F. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13: 1383-1386, 2002.
263. Pollo A, Vighetti S, Rainero I, Benedetti F. Placebo analgesia and the heart. Pain 102: 125-133, 2003.
264. Porro CA, Baraldi P, Pagnoni G, Serafini M, Facchin P, Maieron M, Nichelli P. Does anticipation of pain affect cortical nociceptive systems? J Neurosci 22: 3206-3214, 2002.
265. Porro CA, Cettolo V, Francescato MP, Baraldi P. Functional activity mapping of the mesial hemispheric wall during anticipation of pain. Neuroimage 19: 1738-1747, 2003.
266. Premack D, Woodruff G. Does the chimpanzee have a theory of mind? Behav Brain Sci 1: 515-526, 1978.
267. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science 288: 1769-1772, 2000.
268. Price DD, Craggs J, Verne GN, Perlstein WM, Robinson ME. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 127: 63-72, 2007.
269. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 59: 565-590, 2008.
270. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83: 147-156, 1999.
271. Ramirez-Amaya V, Alvarez-Borda B, Bermudez-Rattoni F. Differential effects of NMDA-induced lesions into the insular cortex and amigdala on the acquisition and evocation of conditioned immunosuppression. Brain Behav Immunity 12: 149-160, 1998.
272. Ramirez-Amaya V, Alvarez-Borda B, Ormsby C, Martinez R, Pèrez-Montfort R, Bermudez-Rattoni F. Insular cortex lesions impair the acquisition of conditioned immunosuppression. Brain Behav Immunity 10: 103-114, 1996.
273. Ramirez-Amaya V, Bermudez-Rattoni F. Conditioned enhancement of antibody production is disrupted by insular cortex and amygdale but not hippocampal lesions. Brain Behav Immunity 13: 46-60, 1999.
274. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy Y, Leibach FH. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51: 723-732, 2002.
275. Reiss S. Pavlovian conditioning and human fear: an expectancy model. Behav Ther 11: 380-396, 1980.
276. Rescorla RA. Pavlovian conditioning: it's not what you think it is. Am Psychologist 43: 151-160, 1988.
277. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, Dogan I, Schreiber F, Hofmann SG, Barsky AJ, Avorn J. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 32: 1041-1056, 2009.
278. Rizzolatti G, Arbib MA. Language within our grasp. Trends Neurosci 21: 188-194, 1998.
279. Rizzolatti G, Craighero L. The mirro-neuron system. Annu Rev Neurosci 27: 169-192, 2004.
280. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18: 247-291, 1993.
281. Ross S, Buckalew LW. Placebo agentry: assessment of drug and placebo effects. In: Placebo: Theory, Research, and Mechanisms, edited by White L, Tursky B, and Schwartz GE, New York: Guilford, 1985, p. 67-82.
282. Sawamoto N, Honda M, Okada T, Hanakawa T, Kanda M, Fukuyama H, Konishi J, Shibasaki H. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulated cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci 20: 7438-7445, 2000.
283. Saxe R. Uniquely human social cognition. Curr Opin Neurobiol 16: 235-239, 2006.
284. Schmale AH Jr, Iker HP. Hopelessness as a predictor of cervical cancer. Social Sci Med 5: 95-100, 1971.
285. Schultz W. Getting formal with dopamine and reward. Neuron 36: 241-263, 2002.
286. Schultz W, Tremblay L, Hollerman JR. Reward processing in primate orbitofrontal cortex and basal ganglia. Cerebral Cortex 10: 272-278, 2000.
287. Schweinhardt P, Seminowicz DA, Jaeger E, Duncan GH, Bushnell MC. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response. J Neurosci 29: 4882-4887, 2009.
288. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55: 325-336, 2007.
289. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 65: 220-231, 2008.
290. Senju A, Johnson MH. The eye contact effect: mechanisms and development. Trends Cogn Sci 13: 127-134, 2009.
291. Shamay-Tsoory SG, Aharon-Peretz J, Perry D. Two systems for empathy: a double dissociation between emotional and cognitive empathy in inferior frontal gyrus versus ventromedial prefrontal lesions. Brain 132: 617-627, 2009.
292. Shapiro AK, Shapiro E. The placebo: is it much ado about nothing? In: The Placebo Effect: An Interdisciplinary Exploration, edited by Harrington A. Cambridge, MA: Harvard Univ. Press, 1997, p. 12-36.
293. Shapiro AK, Shapiro E. The Powerful Placebo: From Ancient Priest to Modern Physician. Baltimore, MD: Johns Hopkins Univ. Press, 1997.
294. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D. The placebo response in Parkinson's disease. Parkinson Study Group Clin Neuropharmacol 22: 207-212, 1999.
295. Siegel S. Explanatory mechanisms for placebo effects: Pavlovian conditioning. In: The Science of the Placebo: Toward an Interdisciplinary Research Agenda, edited by Guess HA, Kleinman A, Kusek JW, and Engel LW, London: British Medical Journal Books, 2002, p. 133-157.
296. Singer T, Seymour B, O'Doherty JP, Kaube H, Dolan RJ, Frith CD. Empathy for pain involves the affective but not sensory components of pain. Science 303: 1157-1162, 2004.
297. Singer T, Seymour B, O'Doherty JP, Stephan KE, Dolan RJ, Frith CD. Empathic neural responses are modulated by the perceived fairness of others. Nature 439: 466-469, 2006.
298. Smith GR, McDaniels SM. Psychologically mediated effect on the delayed hypersensitivity reaction to tuberculin in humans. Psychosom Med 45: 65-70, 1983.
299. Smith WB, Gracely RH, Safer MA. The meaning of pain: cancer patients' rating and recall of pain intensity and affect. Pain 78: 123-129, 1998.
300. Snyder CR. A case for hope in pain, loss, and suffering. In: Perspectives on Loss: A Sourcebook, edited by Harvey JH, Omarzu J, and Miller E. Washington, DC: Taylor & Francis, 1998, p. 63-79.
301. Snyder CR. Hope theory: rainbows in the mind. Psychol Inquiry 13: 249-275, 2002.
302. Snyder CR, Irving L, Anderson JR. Hope and health: measuring the will and the ways. In: Handbook of Social and Clinical Psychology: The Health Perspective, edited by Snyder CR and Forsyth DR. Elmsford, NY: Pergamon, 1991, p. 285-305.
303. Sprecher S, Fehr B. Enhancement of mood and self-esteem as a result of giving and receiving compassionate love. Curr Res Social Psychol 11: 227-242, 2006.
304. Spruijt BM, Van Hoof JARAM, Gispen WH. Ethology and neurobiology of grooming behavior. Physiol Rev 72: 825-852, 1992.
305. Stein N, Sprenger C, Scholz J, Wiech K, Bingel U. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain 153: 2210-2217, 2012.
306. Stein S, Linn MW, Stein EM. Psychological correlates of survival in nursing home cancer patients. Gerontologist 29: 224-228, 1989.
307. Steinberg AD, Huston DP, Taurog JD, Cowdery JS, Raveche ES. The cellular and genetic basis of murine lupus. Immunol Rev 55: 121-154, 1981.
308. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull 130: 324-340, 2004.
309. Stockhorst U, Enck P, Klosterhalfen S. Role of classical conditioning in learning gastrointestinal symptoms. World J Gastroenterol 13: 3430-3437, 2007.
310. Stockhorst U, Gritzmann E, Klopp K, Schottenfeld-Naor Y, Huebinger A, Berresheim HW, Steingrueber HJ, Gries FA. Classical conditioning of insulin effects in healthy humans. Psychosom Med 61: 424-435, 1999.
311. Stockhorst U, Steingruber HJ, Scherbaum WA. Classically conditioned responses following repeated insulin and glucose administration in humans. Behav Brain Res 110: 143-159, 2000.
312. Sunshine A, Laska E, Meisner M, Morgan S. Analgesic studies of indomethacin as analyzed by computer techniques. Clin Pharmacol Ther 5: 699-707, 1964.
313. Tennen H, Affleck G. Finding benefits in adversity. In: Coping: The Psychology of What Works, edited by Snyder CR. New York: Oxford Univ. Press, 1999, p. 279-304.
314. Terman GW, Morgan MJ, Liebeskind JC. Opioid and non-opioid stress analgesia from cold water swim: importance of stress severity. Brain Res 372: 167-171, 1986.
315. Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immunol Rev 55: 179-216, 1981.
316. Thom DH, Campbell B. Patient-physician trust: an exploratory study. J Fam Pract 44: 169-176, 1997.
317. Thompson JJ, Ritenbaugh C, Nichter M. Reconsidering the placebo response from a broad anthropological perspective. Cult Med Psychiatry 33: 112-152, 2009.
318. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 23: 994-1005, 2003.
319. Todorov A. Evaluating faces from trustworthiness. An extension of systems for recognition of emotion signaling approach/avoidance behaviours. Ann NY Acad Sci 1124: 208-224, 2008.
320. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med 16: 1277-1283, 2010.
321. Tranel D, Damasio AR, Damasio H. Intact recognition of facial expression, gender, and age in patients with impaired recognition of face identity. Neurology 38: 690-696, 1988.
322. Trivers RL. The evolution of reciprocal altruism. Q Rev Biol 46: 35-57, 1971.
323. Trousseau A, Gouraud H. Repertoire clinique: experiences homoeopathiques tentées à l'Hotél-Dieu de Paris. J des Connaissances Médico-Chirurgicales 8: 338-341, 1834.
324. Tsao DY, Livingstone MS. Mechanisms of face perception. Annu Rev Neurosci 31: 411-437, 2008.
325. Van Heeringen C, Audenaert K, Van Laere K, Dumont F, Slegers G, Meretens J, Dierckx RA. Prefrontal 5-HT2a receptor binding potential, hopelessness and personality characteristics in attempted suicide. J Affect Disord 74: 149-158, 2003.
326. Van Vugt M, Van Lange PAM. The altruism puzzle: psychological adaptations for prosocial behaviour. In: Evolution and Social Psychology, edited by Schaller M, Simpson JA, and Kenrick DT. New York: Psychology Press, 2006, p. 237-262.
327. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 115: 338-347, 2005.
328. Vits S, Cesko E, Enck P, Hillen U, Schadendorf D, Schedlowski M. Behavioural conditioning as the mediator of placebo responses in the immune system. Philos Trans R Soc Lond B Biol Sci 366: 1799-1807, 2011.
329. Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Jayne M, Telang F, Swanson JM. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 32: 1782-1792, 2006.
330. Volkow ND, Wang GJ, Ma Y, Fowler JS, Zhu W, Maynard L, Telang F, Vaska P, Ding YS, Wong C, Swanson JM. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 23: 11461-11468, 2003.
331. Voudouris NJ, Peck CL, Coleman G. Conditioned response models of placebo phenomena: further support. Pain 38: 109-116, 1989.
332. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain 43: 121-128, 1990.
333. Wager TD, Atlas LY, Leotti LA, Rilling JK. Predicting individual differences in placebo analgesia: contributions of brain activity during anticipation and pain experience. J Neurosci 31: 439-452, 2011.
334. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, Kosslyn SM, Rose RM, Cohen JD. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 303: 1162-1166, 2004.
335. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human (micro)-opioid activity during pain. Proc Natl Acad Sci USA 104: 11056-11061, 2007.
336. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847, 2002.
337. Watson A, El-Deredy W, Vogt BA, Jones AK. Placebo analgesia is not due to compliance or habituation: EEG and behavioural evidence. Neuroreport 18: 771-775, 2007.
338. Watts RL, Freeman TB, Hauser RA, Bakay RAE, Ellias SA, Stoessl AJ, Eidelberg D, Fink JS. A double-blind, randomised, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neurocell-PD) vs. imitation surgery in patients with Parkinson_s disease (PD). Parkinsonism & Related Disorders Suppl 7: S87, 2001.
339. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel I, Kaptchuk TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 365: 119-126, 2011.
340. White L, Tursky B, Schwartz GE. Placebo: Theory, Research, Mechanisms. New York: Guilford, 1985.
341. Whitehouse MW, Levy L, Beck FJ. Effect of cyclophosphamide on a local graft-versushost reaction in the rat: influence of sex, disease and different dosage regimens. Agents Actions 3: 53-60, 1973.
342. Whitman SM. Pain and suffering as viewed by the Hindu religion. J Pain 8: 607-613, 2007.
343. Wiester J. The Genesis Connection. Nashville, TN: Thomas Nelson, 1983.
344. Willer JC, Albe-Fessard D. Electrophysiological evidence for a release of endogenous opiates in stress-induced "analgesia" in man. Brain Res 198: 419-426, 1980.
345. Williams de C AC. Facial expression of pain: an evolutionary account. Behav Brain Sci 25: 439-455, 2002.
346. Willis J, Todorov A. First impressions: making up your mind after 100 ms exposure to a face. Psychol Sci 17: 592-598, 2006.
347. Wilson GT, Niaura RS, Adler JL. Alcohol: selective attention and sexual arousal in men. J Studies Alcohol 46: 107-115, 1985.
348. Winston J, Strange B, O'Doherty J, Dolan R. Automatic and intentional brain responses during evaluation of trustworthiness of face. Nat Neurosci 5: 277-283, 2002.
349. Woods SC. Conditioned hypoglycemia: effect of vagotomy and pharmacological blockade. Am J Physiol 223: 1424-1427, 1972.
350. Woods SC, Makous W, Hutton RA. A new technique for conditioned hypoglycemia. Psychon Sci 10: 389-390, 1968.
351. Woods SC, Makous W, Hutton RA. Temporal parameters of conditioned hypoglycemia. J Comp Physiol Psychol 69: 301-307, 1969.
352. Young AW, Aggleton JP, Hellawell DJ, Johnson M, Broks P, Hanley JR. Face processing impairments after amygdalotomy. Brain 118: 15-24, 1995.
353. Zak PJ, Kurzban R, Matzner WT. The neurobiology of trust. Ann NY Acad Sci 1032: 224-227, 2004.
354. Zhang RR, Zhang WC, Wang JY, Guo JY. The opioid placebo analgesia is mediated exclusively through mu-opioid receptor in rat. Int J Neuropsychopharmacol. In press.
355. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS. Placebo effects mediated by endogenous opioid activity on-opioid receptors. J Neurosci 25: 7754-7762, 2005.
356. Zubieta JK, Stohler CS. Neurobiological mechanisms of placebo responses. Ann NY Acad Sci 1156: 198-210, 2009.